Pharma Mac Pac

pharmamacpac.com

Pharma Mac Pac Expo : International Exhibition & Conference on Pharma Machinery & Packaging. 21st - 23rd November 2013, Hitex Exhibition Centre, Hyderabad, India. Pharma Mac Pac Expo is important for :- Plant & Machinery for Pharmaceutical Production & Processing, Packaging Materials & Machinery, Pollution Control Products & Services, Safety Equipments & Services, Automation & Instrumentation, Automation & Robotics, Batching Equipment, Filling Equipment, Filtration & Separation, Water Purification & Management, Packaging Equipment & Supplies, Plant & Facility Equipment, Tablet & Capsule Fillers

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

PHARMACY MARKET

XERIS PHARMACEUTICALS COMPLETES ENROLLMENT OF ITS PHASE 1 STUDY OF LEVOTHYROXINE (XP-8121)

Xeris Pharmaceuticals, Inc. | September 01, 2021

news image

Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable drug formulations, today announced that the company has completed enrollment and successfully dosed all participants in a Phase 1 study of levothyroxine (XP-8121) to evaluate the pharmacokinetics, safety and tolerability, and potential for weekly dosing of the investigational, novel, subcutaneous (SC) injection for the treatmen...

Read More

BUSINESS INSIGHTS

MATRIC TO ESTABLISH FIRST AND ONLY NATIONAL CENTER OF EXCELLENCE FOR PHARMACEUTICAL PROCESS DESIGN

The Mid-Atlantic Technology, | March 03, 2022

news image

The Mid-Atlantic Technology, Research & Innovation Center announced it will establish the Center of Excellence for process design, defining a new standardized process development framework to streamline chemical manufacturing processes from laboratory bench through to commercial production. The initial projects will develop continuous processes for critical materials for the pharmaceutical industry currently substantially produced overseas. These new capabilities will be established as a res...

Read More

PHARMACY MARKET

FUSION PHARMACEUTICALS AND TRIUMF ANNOUNCE EXPANDED R&D COLLABORATION FOR ACTINIUM SUPPLY PRODUCTION

Fusion Pharmaceuticals Inc. | August 13, 2021

news image

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, and TRIUMF, Canada's particle accelerator centre, today announced that the companies have entered into the next phase of their collaboration agreement for the development, production, and supply of actinium-225. Fusion will provide to TRIUMF funding to further develop technology to produce actinium-225 and in return Fusion will have ...

Read More

PHARMACY MARKET

ARROWHEAD PHARMACEUTICALS INITIATES PHASE 1/2 STUDY OF ARO-C3 FOR TREATMENT OF COMPLEMENT MEDIATED DISEASES

Arrowhead Pharmaceuticals Inc. | February 19, 2022

news image

Arrowhead Pharmaceuticals Inc. announced that it has dosed the first subjects in AROC3-1001, a Phase 1/2 clinical study of ARO-C3, the company’s investigational RNA interference (RNAi) therapeutic designed to reduce production of complement component 3 (C3) as a potential therapy for various complement mediated diseases. “We believe a C3 targeted drug has the potential to address multiple complement mediated and complement associated diseases, whe...

Read More
news image

PHARMACY MARKET

XERIS PHARMACEUTICALS COMPLETES ENROLLMENT OF ITS PHASE 1 STUDY OF LEVOTHYROXINE (XP-8121)

Xeris Pharmaceuticals, Inc. | September 01, 2021

Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable drug formulations, today announced that the company has completed enrollment and successfully dosed all participants in a Phase 1 study of levothyroxine (XP-8121) to evaluate the pharmacokinetics, safety and tolerability, and potential for weekly dosing of the investigational, novel, subcutaneous (SC) injection for the treatmen...

Read More
news image

BUSINESS INSIGHTS

MATRIC TO ESTABLISH FIRST AND ONLY NATIONAL CENTER OF EXCELLENCE FOR PHARMACEUTICAL PROCESS DESIGN

The Mid-Atlantic Technology, | March 03, 2022

The Mid-Atlantic Technology, Research & Innovation Center announced it will establish the Center of Excellence for process design, defining a new standardized process development framework to streamline chemical manufacturing processes from laboratory bench through to commercial production. The initial projects will develop continuous processes for critical materials for the pharmaceutical industry currently substantially produced overseas. These new capabilities will be established as a res...

Read More
news image

PHARMACY MARKET

FUSION PHARMACEUTICALS AND TRIUMF ANNOUNCE EXPANDED R&D COLLABORATION FOR ACTINIUM SUPPLY PRODUCTION

Fusion Pharmaceuticals Inc. | August 13, 2021

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, and TRIUMF, Canada's particle accelerator centre, today announced that the companies have entered into the next phase of their collaboration agreement for the development, production, and supply of actinium-225. Fusion will provide to TRIUMF funding to further develop technology to produce actinium-225 and in return Fusion will have ...

Read More
news image

PHARMACY MARKET

ARROWHEAD PHARMACEUTICALS INITIATES PHASE 1/2 STUDY OF ARO-C3 FOR TREATMENT OF COMPLEMENT MEDIATED DISEASES

Arrowhead Pharmaceuticals Inc. | February 19, 2022

Arrowhead Pharmaceuticals Inc. announced that it has dosed the first subjects in AROC3-1001, a Phase 1/2 clinical study of ARO-C3, the company’s investigational RNA interference (RNAi) therapeutic designed to reduce production of complement component 3 (C3) as a potential therapy for various complement mediated diseases. “We believe a C3 targeted drug has the potential to address multiple complement mediated and complement associated diseases, whe...

Read More